Caribou Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its upcoming participation in two major investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will be featured in fireside chats at both events.
The schedule includes:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, at 11:30 AM ET
- Leerink Global Healthcare Conference on March 11, 2025, at 1:40 PM ET
Both presentations will be available via webcast on the company's website, accessible for at least 30 days following each event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CRBU gained 0.70%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 25, 2025, fireside chat at 11:30 AM ET
Webcast
- Leerink Global Healthcare Conference
March 11, 2025, fireside chat at 1:40 PM ET
Webcast
For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com